Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176462 · ClinicalTrials.gov registry record · Phase 2
CINJALL: Treatment for Children With Acute Lymphocytic Leukemia
A Phase 2 study, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00176462 is a Phase 2 study that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 60 participants.
The verdict
NCT00176462, a Phase 2 study, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this research study is to identify better ways to treat children and young adults with acute lymphocytic leukemia (ALL). At the same time, doctors hope to define methods to identify those patients at higher risk for certain side effects, as well as those who are at higher risk for relapse of their leukemia.
Interventions
- DRUG cyclophosphamide
- DRUG cytarabine
- DRUG L-asparaginase
- DRUG aminopterin
- DRUG daunomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2001-02 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00176462
The ClinicalTrials.gov registry entry for NCT00176462 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00176462 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00176462 about?
NCT00176462 is a clinical study titled "CINJALL: Treatment for Children With Acute Lymphocytic Leukemia". The purpose of this research study is to identify better ways to treat children and young adults with acute lymphocytic leukemia (ALL). At the same time, doctors hope to define methods to identify those patients at higher risk for certain side effects, as well as those who are at higher risk for rel...
What is the current status of trial NCT00176462?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2001-02. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00176462?
The interventions under investigation include: cyclophosphamide (DRUG), cytarabine (DRUG), L-asparaginase (DRUG), aminopterin (DRUG), daunomycin (DRUG).
Who is sponsoring clinical trial NCT00176462?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.